Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$1.6 million.

  • Revolution Medicines' Cash from Financing Activities fell 10205.97% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2213.15%. This contributed to the annual value of $959.4 million for FY2024, which is 2194.82% down from last year.
  • Per Revolution Medicines' latest filing, its Cash from Financing Activities stood at -$1.6 million for Q3 2025, which was down 10205.97% from $256.6 million recorded in Q2 2025.
  • Revolution Medicines' 5-year Cash from Financing Activities high stood at $873.8 million for Q4 2024, and its period low was -$1.6 million during Q3 2025.
  • Its 5-year average for Cash from Financing Activities is $160.0 million, with a median of $10.7 million in 2021.
  • Per our database at Business Quant, Revolution Medicines' Cash from Financing Activities surged by 10619672.13% in 2023 and then plummeted by 10205.97% in 2025.
  • Revolution Medicines' Cash from Financing Activities (Quarter) stood at $10.7 million in 2021, then soared by 378.78% to $51.4 million in 2022, then skyrocketed by 1534.16% to $839.4 million in 2023, then grew by 4.1% to $873.8 million in 2024, then crashed by 100.18% to -$1.6 million in 2025.
  • Its Cash from Financing Activities was -$1.6 million in Q3 2025, compared to $256.6 million in Q2 2025 and $874000.0 in Q1 2025.